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   Φαρμακοδιέγερση σε ίππους: αντιλήψεις, ανεπιθύμητες ενέργειες 
και αναδρομική παρουσίαση κρουσμάτων στην περίοδο 2001-2010 
στον ιππόδρομο στην Κύπρο
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ABSTRACT. Doping in race horses affects thousands of equine athletes worldwide. Illicit administration of medical compounds 
aims to improve the horse’s performance either through altering the athletic capacity, or through covering the symptoms of 
pathologic conditions. Nicosia race track has a significant number of confirmed doping cases when considering the small equine 
population of the island, reflecting the lack of credibility of racing in Cyprus. The most frequently administered medications are 
anabolic steroids, human recombinant erythropoietin, stimulants, diuretics, non-steroidal anti-inflammatory drugs, local anesthet-
ics, bronchodilators and coagulants. Interestingly, published literature on the effectiveness of these substances is inconclusive 
or contradictory. This article constitutes a cumulative presentation of confirmed doping cases in Nicosia race track and a brief 
review on the published literature regarding the effectiveness of the most commonly administered compounds.
Keywords: anabolic steroids; Cyprus racing; equine doping; equine performance manipulation
ΠΕΡΙΛΗΨΗ. Η φαρμακοδιέγερση αθλητικών ίππων αποτελεί διεθνή πραγματικότητα. Η παράνομη χορήγηση φαρμακευτικών 
ουσιών στοχεύει στη βελτίωση της επίδοσης του ίππου είτε μέσω της αύξησης της αθλητικής ικανότητας, είτε μέσω της κάλυ-
ψης συμπτωμάτων που προκαλούν παθολογικές καταστάσεις. Η λέσχη Ιπποδρομιών Λευκωσίας εμφανίζει σημαντικό αριθμό 
επιβεβαιωμένων θετικών δειγμάτων, λαμβανομένου υπόψη του μικρού αριθμού ιπποειδών. Οι συχνότερα χορηγούμενες ουσίες 
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INTRODUCTION
Doping in sport horses is a global reality. It is defined as presence of a prohibited substance or 
its metabolites or markers in an athlete’s bodily spec-
imen. It is believed that thousands of horses suffer 
illicit use of medical substances and methods in order 
to achieve better performance in racing, show jump-
ing, dressage, eventing, and endurance race. From 
these cases only a small percentage is being detected 
with obvious consequences against the responsible 
person(s).
It has been acknowledged that to offer a clean 
game to the horse racing audience, it is imperative 
need to ensure that the best care is provided to the 
equine athlete. International Federation for Equestrian 
Sports which is the international governing body of 
most equestrian sports (excluding horse racing) states 
on its official webpage (http://www.feicleansport.org): 
“Equestrian sport derives its credibility and public 
acceptance from the concept of fair play, the idea that 
the best athlete or team should win fairly and squarely, 
having competed under equitable conditions and under 
rules that are fair and applied evenly with true compe-
tence. To be valid and meaningful, competition results 
must be achieved on a level playing field. Doping and 
the inappropriate use of normal medications present 
a serious threat to the integrity and reputation of our 
sport, because they give athletes an unfair advantage 
and threaten the welfare of horses. Therefore, it is 
the responsibility of the entire equine community: 
athletes, veterinarians, grooms, managers, coaches, 
owners, officials and our National Federations, to join 
together to help combat doping and the inappropri-
ate use of medications through better education and 
increased vigilance.”
The most commonly used substances for horse 
doping can be divided in the following categories: 
(i) substances capable of acting on one of the body 
systems (the nervous s., the cardiovascular s., the 
respiratory s.,  the digestive s., the urinary s., the 
reproductive s., the musculoskeletal s., the blood s., 
the immune s. except for licensed vaccines against 
infectious agents, the endocrine s.; endocrine secre-
tions and their synthetic counterparts) and (ii) sub-
stances capable of covering symptoms of diseases or 
syndromes, such as: (ii.i) anti- pyretics, (ii.ii) local 
anaesthetics and non-steroidal anti-inflammatory 
drugs (NSAIDS) to reduce inflammation and alter 
pain perception, (ii.iii) Analgesics and anti-inflam-
matory substances, (ii.iv) substances affecting blood 
coagulation and diuretics to cover the symptoms of 
exercise induced pulmonary haemorrhage , (ii.v) 
cytotoxic substances, antihistamines, local anaesthet-
ics, muscle relaxants, respiratory stimulants, sex hor-
mones, anabolic agents and corticosteroids.
CURRENT SITUATION IN CYPRUS 
HIPPODROME
Nicosia Race club was founded in the 19th 
century by English Army Officers and since 1960 it 
gained its nowadays structure. anti-doping control 
is a responsibility of the Cyprus Turf Club. A urine 
sample is obtained from the winner of each race, and 
from horses with contradictory performance. The lab 
tests are performed in an independent laboratory in 
the United Kingdom. Detection of substances which 
are included in the prohibited list is convictable.
In the 2001-2010 decade, 1157 meetings with 
9833 races took place in Nicosia race club. In these 
είναι τα αναβολικά στεροειδή, η ανθρώπινη ανασυνδυασμένη ερυθροποιητίνη, τα διεγερτικά, διουρητικά, τα μη στεροειδή αντι-
φλεγμονώδη, τα τοπικά αναισθητικά, τα βρογχοδιασταλτικά και τα πηκτικά του αίματος. Σύμφωνα με τη δημοσιευμένη βιβλιο-
γραφία, η αποτελεσματικότητα αυτών των ουσιών στην αθλητική επίδοση των ίππων είναι ασαφής ή αμφιλεγόμενη. Το άρθρο 
αυτό αποτελεί συγκεντρωτική παρουσίαση των επιβεβαιωμένων θετικών κρουσμάτων φαρμακοδιέγερσης στον κυπριακό ιππό-
δρομο, και μία συνοπτική μελέτη της δημοσιευμένης βιβλιογραφίας σχετικά με την αποτελεσματικότητα των συχνότερα χορη-
γούμενων ουσιών.
Λέξεις ευρετηρίασης: αναβολικά στεροειδή, Κυπριακός ιππόδρομος, παραποίηση αθλητικής απόδοσης, φαρμακοδιέγερση 
ίππων
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sideration. For instance, from a pool of 7346 run-
ners in the 2006-2010 quinquennial, 81 cases were 
confirmed positives (ratio 1:90) while in the British 
race clubs the incidence for the same period was 93 
confirmed cases (British Horseracing, 2006-2010); 
within 474364 runners (ratio 1:5100). Reasonably, 
it is suspected that these numbers are just the tip of 
the iceberg, and a number of cases is not detected as 
samples are rarely obtained from horses with poor 
performance.
The reasons of failure in the anti-doping rule 
in Nicosia race track in the authors’ opinion can be 
summarised as: (i) lack of education of the people 
in the horse racing industry in Cyprus (trainers, 
Jockeys, Owners), (ii) lack of credibility of horse 
racing within Cypriot society, (iii) the penalties for 
anti-doping rule violations are not deterrent and 
(iv) the weaknesses of the anti-doping strategy of 
the authorities. Moreover, the fact that samples are 
obtained only from race winners makes it impossible 
to correlate drug administration and enhanced perfor-
mance, as some non-winning horses may have been 
treated with illegal drugs. It is a fact that most of the 
decision making in horse doping is based on assump-
tions, perception and false expectations. The inter-
national literature on how the most commonly used 
substances are affecting performance is scarce and 
races 13595 runners were recorded with 94800 starts 
(Cyprus Turf Club, 2001-2010). During this peri-
od 161 samples were found positive to substances 
included in the prohibited list (table 1). From these 
samples, 130 were detected with a single substance 
and 31 were detected with multiple substances; 44 
horses were found positive to anabolic steroids (bold-
enone, testosterone, stanozolol), 30 horses were 
found positive to NSAIDS (ketoprofen, flunixin meg-
lumine and phenylbutazone); 21 horses were found 
positive to alkaloids (caffeine, theophylline, theobro-
mine, quinine), 5 horses were found positive to β-2 
adrenergic agonists (clenbuterol, albuterol, formoter-
ol), 5 Horses were positive to carbazochrome and 3 
horses were positive to human recombinant erythro-
poietin. Finally, furosemide was traced in 6 horses. 
Drugs affecting the respiratory, nervous, haemopo-
etic, alimentary, urinary systems, but also anti-hyper-
tensives, muscle relaxants and local anaesthetics were 
also detected. The list also includes butanoic acid, 
atropine, heptaminol, tranexamic acid and verapamil.
DISCUSSION
The number of positive samples during the years 
2001-2010 is considerably high especially if the 
small number of races and starters is taken into con-
Table 1. Analysis of the races, runners, starts and confirmed cases of doping in the Nicosia race club during the period 2001-2010.
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only few studies have been published on this subject. 
Unsurprisingly, for the majority of the substances 
used in Cyprus it is true that no scientific evidence 
exists as to their pharmacokinetic abilities on the 
horse and their actual potential to enhance the perfor-
mance of the equine athlete. Dissemination of these 
results would discourage people involved in equine 
sports industry from using such substances. 
Anabolic steroids
Anabolic steroids are synthetic testosterone ana-
logues. In this study, 44 horses in Nicosia race club 
were found positive to anabolic steroid compounds. 
They are amongst the most frequently used com-
pounds as performance enhancers in horse racing. 
However the benefits of anabolic steroids use in 
sport horses are based on anecdotal documentation. 
Scientific evidence related with the expected positive 
consequences on athletic ability of anabolic steroids 
is rare and the result inconsistent. The physiological 
parameters  response to the anabolic steroids admin-
istration vary, and in most cases not significant alter-
ations are achieved on the parameters which directly 
affect sport horse performance.
A number of studies have investigated the result 
of anabolic steroids on performance. These studies 
investigated potential improvement in terms of direct 
performance improvement and indirect improvement 
through anabolic steroids effect on nitrogen balance, 
weight gain, red blood cell volume, muscle growth, 
and behavior (Pitts and Davis, 2007).
Researchers (Snow et al., 1982a; 1982b) have 
investigated a potential positive effect of anabolic 
steroids on nitrogen balance. One study has shown 
that nitrogen retention was significantly increased 
after anabolic steroid injection. It is speculated that 
anabolic steroids prevent training-related tissue 
breakdown, by promoting positive nitrogen balance. 
In the same studies there was no proven data to 
link anabolic steroids use with weight gain or avoid 
training-related weight loss. Body measurements had 
shown no significant changes between treated horses 
and control group.
Another research group, (Hyppa et al., 1995) 
has investigated the correlation between anabolic 
steroids and red cell volume. Red cell volume was 
increased by 20%. The same study investigated the 
overall effect of anabolic steroids on performance 
ability through red cell volume. Surprisingly, accord-
ing to the results of the study, the increase in red cell 
volume did not lead to increased performance or aer-
obic ability. Aerobic capacity was measured with the 
velocity achieved while heart rate is 200/min (V200); 
control horses showed positive correlation between 
red blood cell volume and performance ability while 
treated horses did not.
The anabolic steroids effect on muscle cells was 
investigated on several studies based on the effects 
they showed on several muscle markers. Muscle 
water content, muscle glycogen content, muscle 
enzyme activity, total mean protein concentration 
and the number of capillaries per unit fiber area were 
not proven to be significantly affected after admin-
istration of anabolic steroids (Snow et al., 1982a; 
Nimmo et al., 1982).
Other measurements with no consistent findings 
regarding anabolic steroids includes blood creatinine 
levels, total protein sodium, chloride, magnesium, 
phosphorus, white blood cell count serum cortisol 
levels, growth hormone levels and peak heart rate 
(pitts and Davis, 2007).
The adverse effects of long term anabolic steroid 
use on horses should not be underestimated. Studies in 
humans and rats suggest that chronic use of anabolic 
steroids leads to a stiffer tendons with lower energy 
absorption potential, increasing the risk of tendon 
injury (Seynnes et al., 2013; Inhofe et al., 1995). 
Additionally, it has been associated with adrenal insuf-
ficiency (Dowling et al. 1993), aggressive behaviour, 
infertility and severe laminitis (Dowling 2002).
Non-steroidal anti-inflammatory drugs
NSaIDs, as antipyretics, analgesics and anti-
inflammatory agents, are among the most commonly 
used medications in equine practice. Musculoskeletal 
injuries are usually treaded with regimens from 
this category such as phenylbutazone, carprofen, 
meloxicam, and flunixin meglumine. The blocking 
action of NSaIDs on prostaglandin synthesis 
and therefore inflammation is achieved through 
cyclooxygenase inhibition in the arachidonic acid 
cascade. Even though musculoskeletal injuries have a 
complex background (age, racetrack surface, gender, 
training regime), it is speculated that NSaIDs are 
18 SpaNOUDES K., DIaKaKIS N.
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been found positive to EPO in the decade 2001-2010.
Caffeine
Caffeine (a xanthine alkaloid to which 7 horses 
were found positive) is also one of the drugs admin-
istered to stimulate horses and achieve better perfor-
mance. In a study (Ferraz et al., 2008), the treatment 
group (n= 6, Arabian horses) received caffeine IV 
at 5 mg/kg 30 minutes prior exercise, while the 
control group of 6 Arabian horses received saline 
IV. The athletic potential of equine athlete is evalu-
ated with the relation between velocity and heart 
rate. Αll horses followed the same exercise proto-
col on treadmill. The results of the study revealed 
that the caffeine-treated horses reached significantly 
increased velocities at the same levels of heart rate 
(10% at 180 beats/min and 11.7% at 200 beats/min) 
compared to the control group. It was also observed 
that caffeine-treated horses had significantly higher 
blood glucose and lower cortisol concentrations; they 
also had lower plasma insulin concentrations. Both 
control horses and caffeine-treated horses groups 
showed increased haematocrit (Hct) during exercise. 
However, exercise alone can lead to Hct alteration 
due to catecholamine induced splenic contraction as 
it can release up to 12 L of blood in the circulation 
(Hodgson et al., 2014). Caffeine induces adrena-
line and noradrenaline release which is a factor that 
increases Hct. However, when administered at a dose 
of 2.5mg/kg (Savage et al., 2005), caffeine failed to 
enhance the performance potential during intense 
exercise.
Furosemide
Furosemide is very often used in race horses. 
During the time period of the study, 8 Nicosia race 
horses were found positive in that substance. The 
expectation from this loop diuretic is to manage 
Exercise Induced pulmonary hemorrhage (EIpH) 
symptoms. The efficacy of this widely abused treat-
ment was investigated in early studies (pascoe 
et al., 1985). In a field trial which included 167 
Thoroughbred horses treated intravenously with 
either furosemide or placebo (saline) it was shown 
that furosemide significantly lowers the risk of EIPH 
incident (Hinchcliff et al., 2009).
Six Standarbred horses with known EIPH his-
associated with increased risk of injury. In a two year 
field study in a Kentucky race track (Dirikolu et al., 
2008), injured horses were found with higher plasma 
concentrations of flunixin and phenylbutazone than 
non-injured horses. Finally, NSAIDs use does not 
come without consequences as they are among the 
etiologies of gastric ulceration (Murray, 1999) and 
renal papillary necrosis (Dowling, 2002).
Erythropoietin
Erythropoietin (EpO) is a peptide hormone. It 
is physiologically produced by kidney interstitial 
fibroblasts as a response to hypoxia if cardiopul-
monary adjustments are not sufficient to prevent 
hypoxemia. The hormone stimulates erythropoiesis 
increasing red blood cell volume, and consequently 
increasing arterial partial pressure of oxygen (paO2). 
Interestingly, training horses in altitude or in very 
intensive regimes would not significantly increase 
EPO production and red blood cell volume. Negative 
feedback mechanisms prevent overproduction of 
EpO.
altitude exercise has only a short term effect 
on EpO production. It is also suggested that EpO 
production is only enhanced during the first day of 
altitude exercise. Cardiorespiratory mechanism is 
capable of responding to the high altitude hypoxia 
after this short period. (Hinchcliff et al., 2008).
In an experiment where human recombinant 
erythropoietin (rhuEpO) was administered three 
times per week for three weeks to four mares 
(McKeever et al., 2006) an increase in red cell vol-
ume and aerobic capacity of the treaded horses is 
reported. In contrast, according to other studies 
(Jaussaud et al., 1994; Souillard et al., 1996), where 
rhuEpO was administered once, no positive altera-
tion in the haemogram was noted.
It is therefore understood that when human 
recombinant erythropoietin is injected to horses, 
resting hematocrit is significantly elevated increas-
ing blood viscosity. Trigger factors such a) splenic 
reserve mobilization and b) diuretic-induced fluid 
losses may lead to sudden death during exercise 
(Hinchcliff et al., 2008). RhuEPO administration to 
horses can potentially induce life-threatening anemia 
due to immune system reaction (Piercy et al. 1998). 
Three horses running in the Nicosia race track have 
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buterol-treated and (iv) control. The study of the 
effects of clenbuterol on aerobic performance was 
based on performing tests like graded exercise test, 
aerobic capacity and exercise capacity test (ECT). 
Interestingly, the outcome of this study was that 
clenbuterol adversely affects aerobic performance, 
high-intensity exercise and the ability of the sport 
horse to recover from exercise, increasing the poten-
tial for cardiac and thermal injury. Moreover, exces-
sive sweating was observed in treated horses while in 
the untreated ones sweating was in normal levels.
Findings of another study based on echocardiog-
raphy (Sleeper et al., 2002) suggest that clenbuterol 
has detrimental effects on equine cardiac function 
causing changes in the structural dimensions increas-
ing risk for aortic rupture.
CONCLUDING REMARKS
Undoubtedly, the doping issue in Cyprus is not 
negligible. The number of positive samples is signifi-
cantly high considering the small size horse popula-
tion. The large number of the trafficking substances, 
the lack of any scientific background of the people 
involved in equine doping and the potential side 
effects from this practice, reveal the inconvenient 
truth: the equine athlete is exposed to every individu-
al’s will to administer potentially harmful substances 
in order to gain advantage against its competition. 
It is well understood that it is a responsibility of the 
authorities to improve testing, in order to protect the 
equine athlete, but also the integrity and credibility 
of the horse racing product.
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tory were included in a clinical trial (perez-Moreno 
et al., 2009), which demonstrated that administra-
tion of furosemide or furosemide – carbazochrome 
(antihemorrhagic agent administered additionally to 
furosemide treatment) combination to horses fails to 
reduce the severity of EIpH symptoms.
Etamsylate
Regardless the lack of scientific evidence, etam-
sylate (a non-thrombogenic anti hemorrhagic drug) 
is administered to racehorses competing in Cyprus 
as a masking agent to cover the epistaxis/bleeding 
caused by EIPH. Etamsylate is also frequently used 
after upper respiratory surgery to control bleeding 
in respiratory tract. In vitro and in vivo effects of 
etasmylate were investigated in a study that recruited 
seven and eight horses respectively (Segura et al., 
2007). Etamsylate in different concentrations was 
incubated with citrated blood and using flow cytom-
etry, P-selectin expression and annexin-V binding 
were measured. In the in vivo leg of this experiment, 
P-selectin expression was measured in blood samples 
obtained prior etasmylate administration and 1 and 
2 hours post IV administration of 12.5 mg/kg eta-
msylate. p-selectin expression, leukocyte-platelet 
aggregate formation and annexin-V binding showed 
a significant increase in the in vitro study, but not in 
the in vivo experimentation.
Clenbuterol
During the time period of the study, 3 horses 
were found positive to clenbuterol. Clenbuterol as a 
β-2 sympathomimetic agent is administered as bron-
chodilator in clinical practice. Based on perceptions, 
it is administered to healthy performance horses, 
in order to increase oxygen intake and therefore to 
increase aerobic performance. The aerobic capacity of 
the athletic horse is determined by the velocity corre-
sponding at 4 mmol/L blood lactate concentration.
Long term effects of the administration of clen-
buterol on performance have been investigated, with 
twenty-three unfit mares taking part in the study 
(Kearns and McKeever, 2002). In this study, the 
horses were divided in four groups: (i) exercise only, 
(ii) clenbuterol-treated only, (iii) exercise and clen-
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